Across TCGA pan-cancer cohorts, TAS2R50 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TAS2R50 data layer compared with 17 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher TAS2R50 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TAS2R50 expression acts as an unfavorable survival marker.

LUSC, SCLC, and SKCM are the cancer types where TAS2R50 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	II,III,IV	0.031	0.733	<.001	10	view →
SCLC	OS	Median	II,III,IV	0.152	0.777	.038	3	view →
SKCM	OS	Median	III,IV	0.233	0.705	.034	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: TAS2R50 tumor-vs-normal RNA expression · all TAS2R50 data types